MCM
FDMT icon

MAI Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

MAI Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168 Buy
+18
New +$157 ﹤0.01% 4655

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MAI Capital Management's FDMT Position: Q1 2026 in Review

MAI Capital Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 18 shares worth $168. The stake represents ﹤0.01% of the portfolio and ranks #4655 among its holdings.

152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • MAI Capital Management held 18 shares of 4D Molecular Therapeutics worth $168 as of Q1 2026.
  • 4D Molecular Therapeutics was a new MAI Capital Management position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4655 holding.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.